Generic Patent Challenges on Blockbuster Drugs and How Drug Companies Successfully Defended Against Them
Join us for a roundtable discussion on the patent strategies that small molecule therapeutics companies with recently-approved or late-stage clinical trial drugs have used to succeed (or fail) in protecting product sales. Our speakers – leaders in life sciences patent and market economics, generic and brand Hatch-Waxman litigation, and late-stage patent strategy – will highlight best practices surrounding market exclusivity and patent protection against generic (ANDA) filers. The webinar will dig deeper into a number of examples where patent protection provided significant market exclusivity beyond the regulatory exclusivities, and will identify the key take-aways for companies that are nearing FDA approval and are poised to launch their commercial products.
1.0 Hour of CA and NY CLE Credit Available.